PURPOSE: Increased ZAP-70 expression predicts poor prognosis in chronic lymphocytic leukemia (CLL). Current methods for accurately measuring ZAP-70 expression are problematic, preventing widespread application of these tests in clinical decision making. We therefore used comprehensive DNA methylation profiling of the ZAP-70 regulatory region to identify sites important for transcriptional control. PATIENTS AND METHODS: High-resolution quantitative DNA methylation analysis of the entire ZAP-70 gene regulatory regions was conducted on 247 samples from patients with CLL from four independent clinical studies. RESULTS: Through this comprehensive analysis, we identified a small area in the 5' regulatory region of ZAP-70 that showed large variability in methylation in CLL samples but was universally methylated in normal B cells. High correlation with mRNA and protein expression, as well as activity in promoter reporter assays, revealed that within this differentially methylated region, a single CpG dinucleotide and neighboring nucleotides are particularly important in ZAP-70 transcriptional regulation. Furthermore, by using clustering approaches, we identified a prognostic role for this site in four independent data sets of patients with CLL using time to treatment, progression-free survival, and overall survival as clinical end points. CONCLUSION: Comprehensive quantitative DNA methylation analysis of the ZAP-70 gene in CLL identified important regions responsible for transcriptional regulation. In addition, loss of methylation at a specific single CpG dinucleotide in the ZAP-70 5' regulatory sequence is a highly predictive and reproducible biomarker of poor prognosis in this disease. This work demonstrates the feasibility of using quantitative specific ZAP-70 methylation analysis as a relevant clinically applicable prognostic test in CLL.
PURPOSE: Increased ZAP-70 expression predicts poor prognosis in chronic lymphocytic leukemia (CLL). Current methods for accurately measuring ZAP-70 expression are problematic, preventing widespread application of these tests in clinical decision making. We therefore used comprehensive DNA methylation profiling of the ZAP-70 regulatory region to identify sites important for transcriptional control. PATIENTS AND METHODS: High-resolution quantitative DNA methylation analysis of the entire ZAP-70 gene regulatory regions was conducted on 247 samples from patients with CLL from four independent clinical studies. RESULTS: Through this comprehensive analysis, we identified a small area in the 5' regulatory region of ZAP-70 that showed large variability in methylation in CLL samples but was universally methylated in normal B cells. High correlation with mRNA and protein expression, as well as activity in promoter reporter assays, revealed that within this differentially methylated region, a single CpG dinucleotide and neighboring nucleotides are particularly important in ZAP-70 transcriptional regulation. Furthermore, by using clustering approaches, we identified a prognostic role for this site in four independent data sets of patients with CLL using time to treatment, progression-free survival, and overall survival as clinical end points. CONCLUSION: Comprehensive quantitative DNA methylation analysis of the ZAP-70 gene in CLL identified important regions responsible for transcriptional regulation. In addition, loss of methylation at a specific single CpG dinucleotide in the ZAP-70 5' regulatory sequence is a highly predictive and reproducible biomarker of poor prognosis in this disease. This work demonstrates the feasibility of using quantitative specific ZAP-70 methylation analysis as a relevant clinically applicable prognostic test in CLL.
Authors: Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps Journal: N Engl J Med Date: 2004-08-26 Impact factor: 91.245
Authors: Liguang Chen; John Apgar; Lang Huynh; Frank Dicker; Teresa Giago-McGahan; Laura Rassenti; Arthur Weiss; Thomas J Kipps Journal: Blood Date: 2004-10-28 Impact factor: 22.113
Authors: R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi Journal: Blood Date: 1999-09-15 Impact factor: 22.113
Authors: Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Bercedis L Peterson; John G Gribben; Vicki A Morrison; Kanti R Rai; Richard A Larson; John C Byrd Journal: J Clin Oncol Date: 2011-02-14 Impact factor: 44.544
Authors: F Fais; F Ghiotto; S Hashimoto; B Sellars; A Valetto; S L Allen; P Schulman; V P Vinciguerra; K Rai; L Z Rassenti; T J Kipps; G Dighiero; H W Schroeder; M Ferrarini; N Chiorazzi Journal: J Clin Invest Date: 1998-10-15 Impact factor: 14.808
Authors: John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson Journal: Blood Date: 2002-07-05 Impact factor: 22.113
Authors: A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt Journal: J Exp Med Date: 2001-12-03 Impact factor: 14.307
Authors: David M Lucas; Amy S Ruppert; Gerard Lozanski; Gordon W Dewald; Arletta Lozanski; Rainer Claus; Christoph Plass; Ian W Flinn; Donna S Neuberg; Elisabeth M Paietta; John M Bennett; Diane F Jelinek; John G Gribben; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman; John C Byrd; Michael R Grever Journal: Leuk Lymphoma Date: 2015-03-30
Authors: Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Veronica Balatti; Lara Rizzotto; Cecelia Miller; Alexey Palamarchuk; Paolo Fadda; Rosantony Pandolfo; Laura Z Rassenti; Erin Hertlein; Amy S Ruppert; Arletta Lozanski; Gerard Lozanski; Thomas J Kipps; John C Byrd; Carlo M Croce; Yuri Pekarsky Journal: Proc Natl Acad Sci U S A Date: 2015-02-02 Impact factor: 11.205
Authors: David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín Journal: Int J Hematol Date: 2015-01-29 Impact factor: 2.490
Authors: David E Frankhouser; Mark Murphy; James S Blachly; Jincheol Park; Mike W Zoller; Javkhlan-Ochir Ganbat; John Curfman; John C Byrd; Shili Lin; Guido Marcucci; Pearlly Yan; Ralf Bundschuh Journal: Bioinformatics Date: 2014-08-31 Impact factor: 6.937